FDA approved Dupixent for the treatment of atopic dermatitis amidst a preemptive lawsuit filed by Sanofi/Regeneron involving the drug and an Amgen patent covering IL-4 inhibitors.
Updated on March 29, 2017
On March 28, 2017 FDA approved Dupixent (dupilumab) for the treatment of adults with moderate to severe atopic dermatitis, Regeneron and Sanofi said in a statement. The monoclonal antibody (mAb) comes in a prefilled syringe, and works by inhibiting interleukin-4 (IL-4) and IL-3. The companies claim Dupixent is the “first and only biologic medicine” approved for the disease.
The Dupixent approval comes in the wake of a preemptive lawsuit filed by Sanofi/Regeneron on March 20, 2017 in a federal court Boston, MA. According to court documents, the companies learned that Amgen, which holds a patent covering IL-4 inhibitors, had hired counsel to litigate a potential case involving an IL-4 inhibitor. Dupixent was the only IL-4 inhibitor expected to come to market soon, and therefore, Sanofi/Regeneron found it likely that Amgen was planning a patent challenge. As a result, Regeneron/Sanofi asked the court to issue a declaratory judgment of non-infringement on Amgen’s patent, allowing Regenerom/Sanofi to market Dupixent without risk of an infringement suit.
The approval of Dupixent comes one day ahead of the drug’s March 29, 2017 PDUFA date. In an emailed statement to Pharmaceutical Technology a spokesperson from Sanofi said "Dupixent will be available later this week in US to patients suffering from moderate to severe atopic dermatitis."
Source: Sanofi/Regeneron
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.